Topline results show GLPG3667 met its primary endpoint in a phase 3-enabling dermatomyositis trial but missed in systemic lupus erythematosus.
Alex Hillenbrand
Advertisement
Alex Hillenbrand is an assistant editor for HCPLive. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.
Articles by Alex Hillenbrand
A BTK inhibitor, orelabrutib, met its primary endpoint in a phase 2b trial for systemic lupus erythematosus, with further approval for a phase 3 trial evaluation.
Advertisement
Latest Updated Articles
GLPG3667 Meets Primary Endpoint in Dermatomyositis, Misses in SLE Phase 3 TrialsPublished: December 19th 2025 | Updated:
Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE TrialPublished: December 15th 2025 | Updated:
Advertisement
Advertisement